Radioterapia externa parcial acelerada en pacientes con cáncer de seno en estado temprano

Objective: In this study, our purpose was to demonstrate the feasibility and effectiveness of external beam partial breast irradiation (PBI) in patients with early-stage breast cancer treated with breast-conserving surgery.Methods: 100 patients were treated with PBI with doses ranging from 35 to 38.5 Gy, in 10 fractions b.i.d. All patients were treated with four non-coplanar fields. The clinical tumor volume was well encompassed within the isodose line of 100 % as well as the planning target volume which was within the isodose line of 95 %.Results: The median follow-up was of 54.3 months. The treatment was well tolerated, with no more than grade I toxicity. So far, there has been one patient with local and axillar recurrence.Conclusions: In our experience, the treatment was well tolerated with low toxicity and with good results, in a shorter treatment time, with the economical benefits this has, especially for populations in developing countries.Objetivo: Demostrar la eficacia y efectividad de la radioterapia parcial acelerada en cáncer temprano de mama en pacientes tratadas con cirugía conservativa.Método: Se trataron cien mujeres con radioterapia externa parcial acelerada, con dosis en un rango de 35 a 38,5 Gy, en 10 fracciones en 5 días dos veces al día con un intervalo de 6 horas. Todas se trataron con 4 campos no cooplanares. El volumen tumoral clínico estuvo cubierto de forma homogénea con la isodosis del 100 %; así mismo el volumen de planeación del blanco, incluido en la isodosis del 95 %.Resultados: El seguimiento promedio fue de 54,3 meses. La tolerancia al tratamiento fue buena y ninguna mujer presentó toxicidad grado 2 o 3. Hasta el momento una paciente presentó recaída ganglionar, local y a distancia.Conclusión: El tratamiento fue bien tolerado, con toxicidad baja y con buenos resultados, en un tiempo corto, con posibles beneficios económicos especialmente en la población de países en vías de desarrollo

Radioterapia externa parcial acelerada en pacientes con cáncer de seno en estado temprano

Objective: In this study, our purpose was to demonstrate the feasibility and effectiveness of external beam partial breast irradiation (PBI) in patients with early-stage breast cancer treated with breast-conserving surgery.Methods: 100 patients were treated with PBI with doses ranging from 35 to 38.5 Gy, in 10 fractions b.i.d. All patients were treated with four non-coplanar fields. The clinical tumor volume was well encompassed within the isodose line of 100 % as well as the planning target volume which was within the isodose line of 95 %.Results: The median follow-up was of 54.3 months. The treatment was well tolerated, with no more than grade I toxicity. So far, there has been one patient with local and axillar recurrence.Conclusions: In our experience, the treatment was well tolerated with low toxicity and with good results, in a shorter treatment time, with the economical benefits this has, especially for populations in developing countries.Objetivo: Demostrar la eficacia y efectividad de la radioterapia parcial acelerada en cáncer temprano de mama en pacientes tratadas con cirugía conservativa.Método: Se trataron cien mujeres con radioterapia externa parcial acelerada, con dosis en un rango de 35 a 38,5 Gy, en 10 fracciones en 5 días dos veces al día con un intervalo de 6 horas. Todas se trataron con 4 campos no cooplanares. El volumen tumoral clínico estuvo cubierto de forma homogénea con la isodosis del 100 %; así mismo el volumen de planeación del blanco, incluido en la isodosis del 95 %.Resultados: El seguimiento promedio fue de 54,3 meses. La tolerancia al tratamiento fue buena y ninguna mujer presentó toxicidad grado 2 o 3. Hasta el momento una paciente presentó recaída ganglionar, local y a distancia.Conclusión: El tratamiento fue bien tolerado, con toxicidad baja y con buenos resultados, en un tiempo corto, con posibles beneficios económicos especialmente en la población de países en vías de desarrollo

High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia

Q2Q1225-232In South America, a high proportion of the population is of Hispanic origin with an important representation in Colombia. Since nothing is known about the contribution of BRCA1 and BRCA2 germline mutations to hereditary breast/ovarian cancer in the Hispanic population from Colombia, we conducted the first study of 53 breast/ovarian cancer families from this country. Comprehensive BRCA mutation screening was performed using a range of techniques, including DHPLC, SSCP, and PTT, followed by DNA sequencing analysis. Thirteen deleterious germline mutations (24.5%) were identified in 53 families, comprising eight in BRCA1 and five in BRCA2. The two recurrent BRCA1 mutations, 3450 delCAAG and A1708E, accounted for 100% of all BRCA1 mutations identified in this cohort and the recurrent 3034 delACAA BRCA2 mutation for 40% of all BRCA2 mutations. Haplotype analyses suggested that each of these mutations has arisen from a common ancestor. The prevalence of BRCA1 or BRCA2 mutations was 50% in multiple case breast cancer families, and was 33% for the breast-ovarian cancer families. Our findings show that BRCA mutations account for a substantial proportion of hereditary breast/ovarian cancer in Colombia. The spectrum of mutations differed completely to that previously reported in Hispanic families of predominantly Mexican origin from Southern California [1] suggesting that specific genetic risk assessment strategies for the different Hispanic populations in South America and in the United States need to be developed